Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,deferredLongTermLiab,goodWill,deferredLongTermAssetCharges,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,changeToOperatingActivities,dividendsPaid,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,epsCurrentYear,exchangeDataDelayedBy,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,GRFS,-2934073000.0,678540032,71810000,,188734000,1773641000,129935000,257141000,533327000,204376000,204376000,,-58700000,,,,37747000,1184734000,980358000,651407000,-15642000,,150987000,129935000,8357163000.0,910728000.0,8940868000.0,5423090000.0,923746000.0,16137599000.0,119604000.0,64734000.0,129935000.0,649057000.0,4262823000.0,142002000.0,380980000.0,1560858000.0,637112000.0,4330055000.0,2423071000.0,3085574000.0,2129789000.0,6077000.0,495777000.0,6730953000.0,2138006000.0,,,,,-64497000.0,-566962000.0,192080000.0,168858000.0,-198667000.0,-23497000.0,21768000.0,177669000.0,81774000.0,-2529000.0,-66956000.0,42237000.0,275000.0,55176000.0,-51556000.0,,,,1524716000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,PREPRE,USD,NMS,"Grifols, S.A.",us_market,2,NasdaqGS,"Grifols, S.A.",EUR,733887,601700,0.45000076,0.031982996,14.07 - 20.49,-5.9699993,-0.2913616,14.07,20.49,1623628800,0.36,29.693253,0.024844721,0.489,1.51,0.99,0,14.666667,3.965,14.922857,-0.40285683,-0.026995959,16.71268,-2.1926804,-0.1311986,13131496448,9.615894,3.662043,15,America/New_York,EDT,-14400000,False,False,0.0,1630526409,14.52,0.0,0.2070441,14.51 - 14.69,14.49,0.0,0.0,13,11,finmb_734865,14.52,1630526403,0.030000687,14.55,14.69,14.51,537746,0.1,,,20.49,14.07,14.92,16.71,733.89k,601.7k,678.54M,,1.1B,0.00%,43.00%,3.98M,7.76,,0.59%,5.17M,0.91,5.20%,0.36,2.48%,1.92,19.17%,"Jun 13, 2021","Jun 02, 2021",2:1,"Jan 03, 2016","Dec 30, 2020","Mar 30, 2021",10.75%,17.34%,3.54%,9.12%,5.23B,3.82,-8.40%,2.26B,1.13B,562.1M,0.49,-30.30%,387.06M,0.28,7.37B,102.38,1.98,3.96,1.18B,662.27M,Value,08174,Healthcare,24000,2,4,"Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",Barcelona,34 93 571 00 00,9,1609372800,1622505600,3,Spain,http://www.grifols.com,86400,3,"Avinguda de la Generalitat, 152",34 93 571 02 67,Drug Manufacturersâ€”General,Parc empresarial Can Sant Joan Sant Cugat del VallEs
t-1,GRFS,-1206014000.0,678540032,80750000,,202629000,1611663000,132863000,261348000,590526000,248428000,248428000,,-89447000,,,,41199000,1309325000,1060897000,718799000,-45799000,,161430000,132863000,982135000.0,910728000.0,8554721000.0,5108392000.0,157717000.0,15274776000.0,119604000.0,67803000.0,688572000.0,627755000.0,3389488000.0,812555000.0,579647000.0,1335138000.0,276929000.0,3433222000.0,3002803000.0,3164954000.0,1980058000.0,11023000.0,504200000.0,5900971000.0,2002281000.0,575515000.0,5332271000.0,149921000.0,601618000.0,34242000.0,-551959000.0,-103311000.0,-133171000.0,-453548000.0,-23497000.0,-27074000.0,258656000.0,39436000.0,27047000.0,-94825000.0,41843000.0,83370000.0,82689000.0,-66909000.0,-27238000.0,-20600000.0,-113230000.0,1829816000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,PREPRE,USD,NMS,"Grifols, S.A.",us_market,2,NasdaqGS,"Grifols, S.A.",EUR,733887,601700,0.45000076,0.031982996,14.07 - 20.49,-5.9699993,-0.2913616,14.07,20.49,1623628800,0.36,29.693253,0.024844721,0.489,1.51,0.99,0,14.666667,3.965,14.922857,-0.40285683,-0.026995959,16.71268,-2.1926804,-0.1311986,13131496448,9.615894,3.662043,15,America/New_York,EDT,-14400000,False,False,0.0,1630526409,14.52,0.0,0.2070441,14.51 - 14.69,14.49,0.0,0.0,13,11,finmb_734865,14.52,1630526403,0.030000687,14.55,14.69,14.51,537746,0.1,,,20.49,14.07,14.92,16.71,733.89k,601.7k,678.54M,,1.1B,0.00%,43.00%,3.98M,7.76,,0.59%,5.17M,0.91,5.20%,0.36,2.48%,1.92,19.17%,"Jun 13, 2021","Jun 02, 2021",2:1,"Jan 03, 2016","Dec 30, 2020","Mar 30, 2021",10.75%,17.34%,3.54%,9.12%,5.23B,3.82,-8.40%,2.26B,1.13B,562.1M,0.49,-30.30%,387.06M,0.28,7.37B,102.38,1.98,3.96,1.18B,662.27M,Value,08174,Healthcare,24000,2,4,"Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",Barcelona,34 93 571 00 00,9,1609372800,1622505600,3,Spain,http://www.grifols.com,86400,3,"Avinguda de la Generalitat, 152",34 93 571 02 67,Drug Manufacturersâ€”General,Parc empresarial Can Sant Joan Sant Cugat del VallEs
t-2,GRFS,-2316477000.0,678540032,71353000,,348855000,1760831000,267436000,239901000,626021000,314767000,314767000,,-23369000,,,,62971000,1353372000,1038605000,727351000,34088000,,285884000,267436000,7663567000.0,910728000.0,8538992000.0,5347090000.0,924594000.0,15646913000.0,119604000.0,43763000.0,348855000.0,566296000.0,3967903000.0,126396000.0,1033195000.0,1244510000.0,319916000.0,4011637000.0,2173983000.0,3643616000.0,2039351000.0,12288000.0,568294000.0,6728186000.0,1986076000.0,,,,,43483000.0,-83093000.0,-47289000.0,-42813000.0,154789000.0,-23497000.0,-30275000.0,310970000.0,80873000.0,-27047000.0,8577000.0,-5191000.0,4476000.0,-95937000.0,-77306000.0,18483000.0,11729000.0,-113230000.0,2399106000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,PREPRE,USD,NMS,"Grifols, S.A.",us_market,2,NasdaqGS,"Grifols, S.A.",EUR,733887,601700,0.45000076,0.031982996,14.07 - 20.49,-5.9699993,-0.2913616,14.07,20.49,1623628800,0.36,29.693253,0.024844721,0.489,1.51,0.99,0,14.666667,3.965,14.922857,-0.40285683,-0.026995959,16.71268,-2.1926804,-0.1311986,13131496448,9.615894,3.662043,15,America/New_York,EDT,-14400000,False,False,0.0,1630526409,14.52,0.0,0.2070441,14.51 - 14.69,14.49,0.0,0.0,13,11,finmb_734865,14.52,1630526403,0.030000687,14.55,14.69,14.51,537746,0.1,,,20.49,14.07,14.92,16.71,733.89k,601.7k,678.54M,,1.1B,0.00%,43.00%,3.98M,7.76,,0.59%,5.17M,0.91,5.20%,0.36,2.48%,1.92,19.17%,"Jun 13, 2021","Jun 02, 2021",2:1,"Jan 03, 2016","Dec 30, 2020","Mar 30, 2021",10.75%,17.34%,3.54%,9.12%,5.23B,3.82,-8.40%,2.26B,1.13B,562.1M,0.49,-30.30%,387.06M,0.28,7.37B,102.38,1.98,3.96,1.18B,662.27M,Value,08174,Healthcare,24000,2,4,"Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",Barcelona,34 93 571 00 00,9,1609372800,1622505600,3,Spain,http://www.grifols.com,86400,3,"Avinguda de la Generalitat, 152",34 93 571 02 67,Drug Manufacturersâ€”General,Parc empresarial Can Sant Joan Sant Cugat del VallEs
t-3,GRFS,-1570799000.0,678540032,74248000,,75869000,1675835000,31867000,233781000,447384000,139355000,139355000,,-55261000,,,,17733000,1384022000,1244667000,936638000,-63486000,,58136000,31867000,1433768000.0,910728000.0,8556735000.0,5364941000.0,428663000.0,15597511000.0,119604000.0,43370000.0,139462000.0,533082000.0,4195147000.0,254449000.0,878406000.0,1240627000.0,215445000.0,4238917000.0,2911500000.0,3554170000.0,1941652000.0,11394000.0,535896000.0,6087705000.0,2085104000.0,,5501972000.0,125032000.0,551905000.0,-56762000.0,-109755000.0,-56967000.0,-68378000.0,240709000.0,-23497000.0,-16499000.0,435341000.0,80642000.0,8912000.0,325563000.0,-73425000.0,-11411000.0,139185000.0,-75734000.0,-18483000.0,-11729000.0,-113230000.0,2313543000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,PREPRE,USD,NMS,"Grifols, S.A.",us_market,2,NasdaqGS,"Grifols, S.A.",EUR,733887,601700,0.45000076,0.031982996,14.07 - 20.49,-5.9699993,-0.2913616,14.07,20.49,1623628800,0.36,29.693253,0.024844721,0.489,1.51,0.99,0,14.666667,3.965,14.922857,-0.40285683,-0.026995959,16.71268,-2.1926804,-0.1311986,13131496448,9.615894,3.662043,15,America/New_York,EDT,-14400000,False,False,0.0,1630526409,14.52,0.0,0.2070441,14.51 - 14.69,14.49,0.0,0.0,13,11,finmb_734865,14.52,1630526403,0.030000687,14.55,14.69,14.51,537746,0.1,,,20.49,14.07,14.92,16.71,733.89k,601.7k,678.54M,,1.1B,0.00%,43.00%,3.98M,7.76,,0.59%,5.17M,0.91,5.20%,0.36,2.48%,1.92,19.17%,"Jun 13, 2021","Jun 02, 2021",2:1,"Jan 03, 2016","Dec 30, 2020","Mar 30, 2021",10.75%,17.34%,3.54%,9.12%,5.23B,3.82,-8.40%,2.26B,1.13B,562.1M,0.49,-30.30%,387.06M,0.28,7.37B,102.38,1.98,3.96,1.18B,662.27M,Value,08174,Healthcare,24000,2,4,"Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",Barcelona,34 93 571 00 00,9,1609372800,1622505600,3,Spain,http://www.grifols.com,86400,3,"Avinguda de la Generalitat, 152",34 93 571 02 67,Drug Manufacturersâ€”General,Parc empresarial Can Sant Joan Sant Cugat del VallEs
